Identifying implications of thrombolysis for stroke rehabilitation: Knowledge gaps in current research

Its been 17 years since tPA has been approved and there still is no knowledge of how effective it is long term. Who's in charge? Obviously not a stroke survivor. So ask your doctor  what your recovery prognosis is based on your use of tPA.


http://www.ncbi.nlm.nih.gov/pubmed/23061414

Abstract

Purpose: Thrombolysis with tissue plasminogen activator (rtPA) is currently used throughout the world in acute ischaemic stroke management. In this review, we will explore the status of our current knowledge about the effects of rtPA on specific rehabilitation domains and highlight some key knowledge gaps. Methods: Narrative review of the larger clinical and postmarketing surveillance studies. Results: To date, most of the previous research into rtPA for acute ischaemic stroke has focused on safety and efficacy using general outcome measures and has ceased following patients 90 days after rtPA administration. This research has provided valuable information about the safety and efficacy of rtPA and has facilitated the introduction of rtPA into clinical practice for stroke management. However there is a paucity of knowledge about the long-term recovery patterns of patients post-rtPA, including the effect of rtPA on specific rehabilitation domains and its impact on post-acute service delivery. Furthermore, limited information is available about the effect of rtPA on post-stroke quality of life and participation in society. Conclusion: These knowledge gaps have substantial implications for the long-term management of patients by rehabilitation teams. Increasing our knowledge in these areas may assist us to predict which individuals are most likely to benefit from thrombolysis with rtPA, and enable us to provide optimal rehabilitation programs to maximise functional outcomes and quality of life post-stroke.